Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2022; 10(29): 10550-10558
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10550
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10550
Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
Zhe Zhang, Chang-Qing Zheng, The Second Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Zhang Z reviewed the literature and contributed to the draft of the manuscript; Zheng CQ was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang-Qing Zheng, PhD, Doctor, The Second Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang 110004, Liaoning Province, China. zhengchangqing88@163.com
Received: September 17, 2021
Peer-review started: September 17, 2021
First decision: December 9, 2021
Revised: December 22, 2021
Accepted: September 7, 2022
Article in press: September 7, 2022
Published online: October 16, 2022
Peer-review started: September 17, 2021
First decision: December 9, 2021
Revised: December 22, 2021
Accepted: September 7, 2022
Article in press: September 7, 2022
Published online: October 16, 2022
Core Tip
Core Tip: With its good efficacy, immunotherapy is increasingly being used in treating malignant tumors and attention shall be paid to the immune-related side effects caused by this therapy. This is a report on Sintilimab and Carrelizumab induced colitis which has rarely been reported in the past. Besides, a positive effect was achieved by adopting Vedolizumab combined with short-term corticosteroids therapy, which was different from the previous treatment.